Efficacy of “Essential Iodine Drops” against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)
Köntös,
Efficacy of “Essential Iodine Drops” against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2),
, Z., PLOS ONE, doi:10.1371/journal.pone.0254341 (In Vitro)
Köntös et al., 9 Jul 2021, Hungary, peer-reviewed, 1 author.
Contact:
zkontos@ioi-investment.com.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: PLOS ONE
RESEARCH ARTICLE
Efficacy of “Essential Iodine Drops” against
Severe Acute Respiratory SyndromeCoronavirus 2 (SARS-CoV-2)
Zoltán Köntös*
IOI Investment Zrt., Fehérvári út, Budapest, Hungary
* zkontos@ioi-investment.com
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Köntös Z (2021) Efficacy of “Essential
Iodine Drops” against Severe Acute Respiratory
Syndrome-Coronavirus 2 (SARS-CoV-2). PLoS
ONE 16(7): e0254341. https://doi.org/10.1371/
journal.pone.0254341
Editor: Raffaele Serra, University Magna Graecia of
Catanzaro, ITALY
Received: November 3, 2020
Accepted: June 25, 2021
Published: July 9, 2021
Copyright: © 2021 Köntös Zoltán. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript.
Funding: This study was funded by IOI Investment
Zrt., who also provided support for this study in the
form of salary for ZK. The specific roles of these
authors are articulated in the ‘author contributions’
section. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have read the
journal’s policy and the authors of this manuscript
have the following competing interests: ZK is a paid
Abstract
Background
Aerosolization of respiratory droplets is considered the main route of coronavirus disease
2019 (COVID-19). Therefore, reducing the viral load of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) shed via respiratory droplets is potentially an ideal
strategy to prevent the spread of the pandemic. The in vitro virucidal activity of intranasal
Povidone-Iodine (PVP-I) has been demonstrated recently to reduce SARS-CoV-2 viral
titres. This study evaluated the virucidal activity of the aqueous solution of Iodine-V (a clathrate complex formed by elemental iodine and fulvic acid) as in Essential Iodine Drops (EID)
with 200 μg elemental iodine/ml content against SARS-CoV-2 to ascertain whether it is a
better alternative to PVP-I.
Methods
SARS-CoV-2 (USAWA1/2020 strain) virus stock was prepared by infecting Vero 76 cells
(ATCC CRL-1587) until cytopathic effect (CPE). The virucidal activity of EID against SARSCoV-2 was tested in three dilutions (1:1; 2:1 and 3:1) in triplicates by incubating at room temperature (22 ± 2˚C) for either 60 or 90 seconds. The surviving viruses from each sample
were quantified by a standard end-point dilution assay.
Results
EID (200 μg iodine/ml) after exposure for 60 and 90 seconds was compared to controls. In
both cases, the viral titre was reduced by 99% (LRV 2.0). The 1:1 dilution of EID with virus
reduced SARS-CoV-2 virus from 31,623 cell culture infectious dose 50% (CCID50) to 316
CCID50 within 90 seconds.
Conclusion
Substantial reductions in LRV by Iodine-V in EID confirmed the activity of EID against
SARS-CoV-2 in vitro, demonstrating that Iodine-V in EID is effective at inactivating the virus
in vitro and therefore suggesting its potential application intranasally to reduce SARS-CoV-2
transmission from known or suspected COVID-19 patients.
PLOS ONE | https://doi.org/10.1371/journal.pone.0254341 July 9, 2021
1/7
PLOS ONE
employee of IOI Investment Zrt, the manufacturing
company of Iodine-V and EID...
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit